Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 37 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/29/2008 First Published: 12/8/2006


1.		Phase III/IV Randomized Study of Risk-Adapted Therapy Comprising Observation Only, Combination Chemotherapy, Radiotherapy, and/or Autologous Stem Cell Transplantation in Younger Patients With Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV, Phase III				Treatment				Active				21 and under				Other				GPOH-NB2004 EU-20661, NCT00410631


2.		Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Active				18 and over				Other				2006-00055-18 NCT00415103


3.		Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Active				18 to 75				Other				UMCN-AKF 07.02 EudraCTnr 2007-003347-73, NCT00588835

Last Modified: 4/28/2008 First Published: 5/21/2007


4.		Phase II/III Randomized Study of Therapy Optimization Comprising Induction, Consolidation, and Intensification Regimens Followed By CNS Radiotherapy and Maintenance Therapy Comprising Thioguanine and Cytarabine in Pediatric Patients With Standard-Risk or High-Risk Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and under				Other				UCHM-AML-BFM-2004 UCHM-BfArM 4022064, NCT00111345, UCHM-DKH 50-2728, EU-20723, AML-BFM 2004


5.		High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				25 to 65				Other				JALSG ALL202-O NCT00131027

Last Modified: 9/19/2008 First Published: 3/3/2006


6.		Phase III Study of Doxorubicin Hydrochloride, Vincristine, Prednisone, and Cyclophosphamide Followed by Radiotherapy and/or Response-Directed Chemotherapy in Children and Adolescents With Newly Diagnosed Low-Risk Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				21 and under				NCI				COG-AHOD0431 AHOD0431, NCT00302003

Last Modified: 6/19/2008 First Published: 2/5/2007


7.		Phase III Randomized Study of Combination Chemotherapy in Pediatric Patients With Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Diagnostic, Treatment				Active				Under 18				Other				EURONET-PHL-C1 EU-20703, EUDRACT-2006-000995-33, NCT00433459, CCLG-HD-2007-10

Last Modified: 8/25/2008 First Published: 4/2/2008


8.		Phase III Study of Induction Therapy Comprising Vincristine, High-Dose Methotrexate, Leucovorin Calcium, Etoposide, Cisplatin, and Cyclophosphamide Followed by 3-Dimensional Conformal Radiotherapy and High-Dose Consolidation Therapy Comprising Carboplatin, Thiotepa, and Autologous Peripheral Blood Stem Cell Rescue in Pediatric Patients With Atypical Teratoid/Rhabdoid Tumors of the Central Nervous System

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Approved-not yet active				21 and under at the time of definitive surgery				NCI				COG-ACNS0333 ACNS0333, NCT00653068


9.		Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-Cisplatin for Extensive Disease Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				D0750018 D0750018, NCT00660504


10.		A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				30 and under				NCI, Other				OS2008 NCT00667342

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute